- Home
- RDI vs RADX Comparison
RDI vs RADX Comparison
Compare RDI & RADX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDI
- RADX
- Stock Information
- Founded
- RDI 1937
- RADX 2021
- Country
- RDI United States
- RADX Australia
- Employees
- RDI N/A
- RADX N/A
- Industry
- RDI Movies/Entertainment
- RADX
- Sector
- RDI Consumer Discretionary
- RADX
- Exchange
- RDI Nasdaq
- RADX NYSE
- Market Cap
- RDI 30.6M
- RADX 32.5M
- IPO Year
- RDI N/A
- RADX N/A
- Fundamental
- Price
- RDI $1.28
- RADX $4.05
- Analyst Decision
- RDI Hold
- RADX Strong Buy
- Analyst Count
- RDI 1
- RADX 2
- Target Price
- RDI $2.40
- RADX $13.50
- AVG Volume (30 Days)
- RDI 30.6K
- RADX 22.6K
- Earning Date
- RDI 08-13-2025
- RADX 02-26-2025
- Dividend Yield
- RDI N/A
- RADX N/A
- EPS Growth
- RDI N/A
- RADX N/A
- EPS
- RDI N/A
- RADX N/A
- Revenue
- RDI $205,644,000.00
- RADX $204,609.00
- Revenue This Year
- RDI $7.47
- RADX N/A
- Revenue Next Year
- RDI $13.22
- RADX N/A
- P/E Ratio
- RDI N/A
- RADX N/A
- Revenue Growth
- RDI N/A
- RADX N/A
- 52 Week Low
- RDI $1.17
- RADX $3.50
- 52 Week High
- RDI $1.89
- RADX $50.82
- Technical
- Relative Strength Index (RSI)
- RDI 44.08
- RADX N/A
- Support Level
- RDI $1.21
- RADX N/A
- Resistance Level
- RDI $1.37
- RADX N/A
- Average True Range (ATR)
- RDI 0.06
- RADX 0.00
- MACD
- RDI -0.01
- RADX 0.00
- Stochastic Oscillator
- RDI 35.00
- RADX 0.00
About RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.
About RADX RADIOPHARM THERANOSTICS LIMITED SPON ADS EACH REP 300 ORD
Radiopharm Theranostics Ltd is an Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialization of health technologies.